Cardlytics (NASDAQ:CDLX) Lowered to “Hold” at ValuEngine

ValuEngine downgraded shares of Cardlytics (NASDAQ:CDLX) from a buy rating to a hold rating in a research note issued to investors on Wednesday, September 4th, ValuEngine reports.

A number of other research analysts also recently issued reports on CDLX. Zacks Investment Research downgraded Cardlytics from a buy rating to a hold rating in a research note on Tuesday, July 23rd. Bank of America restated a buy rating and issued a $32.00 price target (up from $22.00) on shares of Cardlytics in a research note on Wednesday, July 24th. KeyCorp upped their price target on Cardlytics from $25.00 to $26.00 and gave the stock an overweight rating in a research note on Friday, May 10th. SunTrust Banks upped their price target on Cardlytics from $25.00 to $35.00 and gave the stock a buy rating in a research note on Friday, August 9th. Finally, William Blair assumed coverage on Cardlytics in a research note on Monday, July 1st. They issued an outperform rating for the company. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $33.29.

Shares of NASDAQ CDLX traded down $0.01 during midday trading on Wednesday, hitting $37.46. 793 shares of the company’s stock traded hands, compared to its average volume of 532,278. Cardlytics has a 1 year low of $9.80 and a 1 year high of $39.62. The stock has a market capitalization of $855.44 million, a price-to-earnings ratio of -17.48 and a beta of 1.55. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.01 and a current ratio of 2.01. The firm has a fifty day moving average of $32.99 and a 200 day moving average of $23.66.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. The firm had revenue of $48.73 million during the quarter, compared to analyst estimates of $43.77 million. During the same quarter in the prior year, the firm earned ($0.21) EPS. The business’s revenue for the quarter was up 37.0% compared to the same quarter last year. On average, equities analysts anticipate that Cardlytics will post -1.08 earnings per share for the current year.

In related news, Director Bryce Youngren sold 135,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $34.99, for a total transaction of $4,723,650.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Scott D. Grimes sold 10,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $34.04, for a total value of $340,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,354,392 shares of company stock valued at $72,349,708 over the last quarter. Corporate insiders own 21.90% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in CDLX. Bank of Montreal Can increased its stake in Cardlytics by 16,371.4% in the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock worth $30,000 after purchasing an additional 1,146 shares during the period. Oppenheimer Asset Management Inc. bought a new stake in Cardlytics during the second quarter valued at about $60,000. Rockefeller Capital Management L.P. bought a new stake in Cardlytics during the second quarter valued at about $85,000. Acadian Asset Management LLC bought a new stake in Cardlytics during the second quarter valued at about $161,000. Finally, Gamco Investors INC. ET AL bought a new stake in Cardlytics during the first quarter valued at about $256,000. Institutional investors and hedge funds own 85.01% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: What are retained earnings?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.